Edition:
United States

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.43USD
8 Dec 2017
Change (% chg)

$0.02 (+1.42%)
Prev Close
$1.41
Open
$1.41
Day's High
$1.45
Day's Low
$1.41
Volume
278,347
Avg. Vol
661,102
52-wk High
$1.77
52-wk Low
$0.73

Latest Key Developments (Source: Significant Developments)

Novavax CEO Stanley Erck reports open market purchase of 100,000 co's common shares
Monday, 13 Nov 2017 08:40am EST 

Nov 13 (Reuters) - Novavax Inc :Novavax Inc says CEO Stanley Erck reports open market purchase of 100,000 co's common shares at average price of $1.13per share on november 9 - sec filing.  Full Article

Novavax reports Q3 loss per share $0.15
Tuesday, 7 Nov 2017 04:06pm EST 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue $8.4 million versus $3.2 million.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Novavax Q3 loss per share $0.15
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Novavax Inc ::Novavax reports third quarter 2017 financial results.Q3 loss per share $0.15.Q3 revenue $8.4 million versus $3.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 revenue view $6.4 million -- Thomson Reuters I/B/E/S.Novavax - ‍as of Sept 30, 2017, co had $172.6 million in cash, cash equivalents and marketable securities, compared to $235.5 million as of Dec 31, 2016​.  Full Article

Novavax announces leadership change
Friday, 13 Oct 2017 07:30am EDT 

Oct 13 (Reuters) - Novavax Inc ::Novavax announces leadership change.Novavax Inc - ‍Barclay Phillips has submitted his resignation as senior vice president, chief financial officer (CFO) and treasurer​.Novavax Inc - ‍Erck will act as interim CFO pending completion of a search for a new chief financial officer​.  Full Article

Novavax initiates phase 1/2 trial of Nanoflu vaccine in older adults
Tuesday, 19 Sep 2017 09:05am EDT 

Sept 19 (Reuters) - Novavax Inc :Novavax initiates phase 1/2 trial of Nanoflu vaccine in older adults.Novavax Inc - ‍data from phase 1/2 trial of Nanoflu expected by end of 2017.  Full Article

Novavax reports Q2 loss per share $0.16
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Novavax Inc -:Novavax reports second quarter 2017 financial results.Q2 loss per share $0.16.Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q2 revenue $6.7 million versus I/B/E/S view $6.3 million.  Full Article

Novavax Q2 loss per share $0.16
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Novavax Inc :Novavax reports second quarter 2017 financial results.Q2 loss per share $0.16.Q2 revenue $6.7 million versus i/b/e/s view $6.3 million.Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Novavax announces positive topline data from phase 2 trial and provides path forward for RSV F vaccine programs
Monday, 24 Jul 2017 04:05pm EDT 

July 24 (Reuters) - Novavax Inc :Novavax announces positive topline data from phase 2 older adult trial and provides path forward for RSV F vaccine programs.  Full Article

Novavax reports Q1 loss per share $0.16
Monday, 8 May 2017 04:12pm EDT 

May 8 (Reuters) - Novavax Inc :Novavax reports first quarter 2017 financial results.Q1 loss per share $0.16.Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Q1 revenue $5.7 million versus I/B/E/S view $6.2 million.Novavax- As of March 31, 2017, had $211.2 million in cash and cash equivalents and marketable securities compared to $235.5 million as of December 31, 2016.  Full Article

Novavax reports Q1 loss per share $0.16
Monday, 8 May 2017 04:05pm EDT 

May 8 (Reuters) - Novavax Inc :Novavax reports first quarter 2017 financial results.Q1 loss per share $0.16.Q1 revenue $5.7 million versus i/b/e/s view $6.2 million.Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S